
Claims

1. Use of (R)-Compound 1 in the manufacture of a medicament for the treatment of hypertension or primary aldosteronism in a human having a mean seated blood pressure of ≥130/80 mmHg, wherein 1 mg/day, 2 mg/day or 4 mg/day of (R)-Compound 1 is to be administered to the human:



(R)-Compound 1.

2. The use of claim 1, wherein the human is on a stable background hypertensive regimen prior to the administration of the (R)-Compound 1.
3. The use of claim 2, wherein the stable background hypertensive regimen comprises ≥3 antihypertensive agents.
4. The use of claim 3, wherein one of the antihypertensive agents is a diuretic.
5. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease from baseline in seated systolic blood pressure (SBP) after 4 weeks of treatment.
6. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease from baseline in seated systolic blood pressure (SBP) after 12 weeks of treatment.
7. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease in baseline in seated diastolic blood pressure (DBP) after 4 weeks of treatment.
8. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a mean decrease in baseline in seated diastolic blood pressure (DBP) after 12 weeks of treatment.
9. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a seated blood pressure (BP) of <130/80 mmHg after 4 weeks of treatment.

10. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 results in a seated blood pressure (BP) of <130/80 mmHg after 12 weeks of treatment.

11. The use of any one of claims 1 to 10, wherein about 1 mg/day of (R)-Compound 1 is to be administered to the human.

12. The use of any one of claims 1 to 10, wherein about 2 mg/day of (R)-Compound 1 is to be administered to the human.

13. The use of any one of the preceding claims, wherein the amount of (R)-Compound 1 is to be administered to the human in a single dose.

14. The use of any one of the preceding claims, wherein the administration of the (R)-Compound 1 does not result in a clinically significant adverse event in the human.

15. The use of any one of the preceding claims, wherein the human is at least 18 years of age.

16. The use of any one of the preceding claims, wherein hypertension is treated.

17. The use of any one of the preceding claims, wherein primary aldosteronism is treated.

18. A pharmaceutical composition comprising 1 mg, 2 mg or 4 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.

19. The pharmaceutical composition of claim 18 comprising 1 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.

20. The pharmaceutical composition of claim 18 comprising 2 mg of (R)-Compound 1 and a pharmaceutically acceptable excipient.